Skip to content

Early Use of Airway Pressure Release Ventilation (APRV) in ARDS

Early Use of Airway Pressure Release Ventilation (APRV) in Patients With Acute Respiratory Distress Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04221737
Enrollment
150
Registered
2020-01-09
Start date
2017-07-15
Completion date
2026-12-01
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Keywords

Acute Respiratory Distress Syndrome, Acute Lung Injury, Mechanical Ventilation, APRV

Brief summary

Airway pressure release ventilation (APRV) is a time-cycled, pressure controlled, intermittent mandatory ventilation mode with extreme inverse I:E ratios. Currently it is considered as a non-conventional ventilatory mode. The investigators aim to compare APRV with conventional mechanical ventilation (MV) in patients with acute respiratory distress syndrome (ARDS).

Detailed description

Despite the advances in technology and ventilatory modes, mortality of ARDS is still around 40%. Besides prone positioning, the best approach of management is low tidal volume ventilation (LTV). This 'protective ventilation' strategy is not aways effective to improve oxygenation and is associated with an increased requirement of sedation and neuromuscular blocking agents, which increase length of stay and morbidity. APRV is a ventilatory mode based on relatively high and sustained continuous positive pressure, combined with a short phase of release to allow carbon dioxide removal. It also allows unrestricted spontaneous breathing throughout respiration, independent of the ventilator cycle. Providing sustained inflation while limiting duration and frequency of release phase permits limiting volume loss, resulting in progressive and improved alveolar recruitment, an increased alveolar surface area available for gas exchange and improved ventilation-perfusion matching. In this multi-center, prospective, randomized, controlled, open trial, the investigators aim to compare the effects and safety of the early application of time-controlled adaptive method of APRV and conventional ventilation with LTV strategy in patients with severe to moderate ARDS.

Interventions

DEVICEAPRV. General Electric Healthcare Engstrom ventilator system

APRV consist of an extended time at plateau pressure (a continuous positive airway pressure phase) comprising about 90% of the respiratory cycle, while providing very brief releases to enhance carbon dioxide removal. Time-controlled adaptive method requires interpretation of the expiratory flow curve to assess changes in lung elastance and, therefore, set the Time low to optimize carbon dioxide removal, but not at the expense of alveolar derecruitment and instability.

DEVICEConventional. General Electric Healthcare Engstrom ventilator system

Lung protective ventilation consist of delivery of low tidal volumes (4-6 ml/kg PBW), high PEEP enough to avoid de-recruitment, titrated according to ARDSNet PEEP/fraction of inspired oxygen (FiO2) table, while avoiding excessive transpulmonary pressure.

Sponsors

Hospital Civil de Guadalajara
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Acute respiratory distress syndrome, according to the Berlin definition of ARDS, with adjusted pO2/FiO2 for altitude \<300, and less than 48 h of endotracheal mechanical ventilation

Exclusion criteria

* Pregnancy * Less than 18 years-old * Expected duration of mechanical ventilation less than 48 h * Preexisting conditions with an expected 3-month mortality exceeding 50% * Concurrent chemotherapy * Confirmed intracranial hypertension * Catastrophic cranial trauma or neuromuscular disorders that are known to prolong mechanical ventilation * Pneumothorax at enrollment (resolved or not) * Do-not-resuscitate order

Design outcomes

Primary

MeasureTime frame
Mechanical ventilation free days28 days

Secondary

MeasureTime frameDescription
All causes mortality28 days
ICU length of stay28 days
Hospital length of stay60 days
Mean airway pressure, peak airway pressure, maximum P high7 daysMeasured in cmH20
Average expiratory time7 daysMeasured in seconds
Minute ventilation7 days
oxygen partial pressure (pO2)7 days
pCO2 (carbon dioxide partial pressure)7 days
Mean arterial pressure7 days
Maximum dosage of vasopressors requirement7 days
Richmond Sedation-Agitation Scale7 daysRange from -5 (unarousable) to +4 (combative)
Average dose of propofol use7 days
Rate of neuromuscular blocking agents utilization7 days
Prone position rate7 days
Average of prone position sessions7 days
Rate of recruitment maneuvers7 days
Tracheostomy rate28 days

Countries

Mexico

Contacts

CONTACTMiguel Ibarra-Estrada, Dr
drmiguelibarra@hotmail.com3317593502
CONTACTGuadalupe Aguirre-Avalos, Dr
guadalupe.aavalos@academicos.udg.mx
PRINCIPAL_INVESTIGATORMiguel Ibarra-Estrada, Dr

Hospital Civil Fray Antonio Alcalde

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026